Source comparison
BPC-157 for Carpal Tunnel: Research Peptide Comparison
BPC-157 VEGF upregulation, collagen synthesis, angiogenesis, NO pathway modulation 250–500 mcg/day SC 4–6 hours Animal studies (tendon, ligament, nerve). No human RCTs Strongest preclinical data for tissue repair. Widely used for musculoskeletal injuries TB-50
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, collagen synthesis, angiogenesis, NO pathway modulation
- 250–500 mcg/day SC
- 4–6 hours
- Animal studies (tendon, ligament, nerve). No human RCTs
- Strongest preclinical data for tissue repair. Widely used for musculoskeletal injuries
- TB-500 (Thymosin Beta-4)
- Actin regulation, cell migration, angiogenesis
- 2–5 mg/week SC
- 2–4 hours
- Animal studies. Minimal human data
- Promotes cell migration and wound healing. Often stacked with BPC-157
- Cerebrolysin
- Neurotrophic factors (BDNF, NGF mimetics)
- 5–30ml IV (clinical doses)
- 2–3 hours
- Human trials for stroke, TBI. Not peripheral nerve injury
- Neurotrophic support for CNS injuries. Not practical for carpal tunnel
- Semax
- BDNF upregulation, neuroprotection
- 300–600 mcg intranasal
- 1–2 hours
- Animal studies + limited human trials for cognition
- Cognitive enhancement focus. No direct peripheral nerve repair data
- Standard Care (Splinting, Steroids, Surgery)
- Mechanical decompression, inflammation suppression
- Varies
- N/A
- RCT-level evidence
- Gold standard for symptom relief. Doesn't accelerate nerve healing